Carisma Therapeutics (NASDAQ:CARM – Get Free Report) and ProPhase Labs (NASDAQ:PRPH – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.
Profitability
This table compares Carisma Therapeutics and ProPhase Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Carisma Therapeutics | -314.78% | -957.20% | -96.39% |
| ProPhase Labs | -217.64% | -62.92% | -30.22% |
Institutional and Insider Ownership
44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 12.6% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 20.7% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Carisma Therapeutics | 0 | 5 | 1 | 1 | 2.43 |
| ProPhase Labs | 0 | 0 | 0 | 0 | 0.00 |
Carisma Therapeutics currently has a consensus price target of $1.93, suggesting a potential upside of 884.15%. Given Carisma Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than ProPhase Labs.
Earnings & Valuation
This table compares Carisma Therapeutics and ProPhase Labs”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Carisma Therapeutics | $19.96 million | 0.41 | -$86.88 million | ($1.56) | -0.13 |
| ProPhase Labs | $5.85 million | 2.49 | -$16.78 million | ($1.26) | -0.28 |
ProPhase Labs has lower revenue, but higher earnings than Carisma Therapeutics. ProPhase Labs is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Carisma Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.47, indicating that its share price is 147% less volatile than the S&P 500.
Summary
Carisma Therapeutics beats ProPhase Labs on 8 of the 15 factors compared between the two stocks.
About Carisma Therapeutics
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
About ProPhase Labs
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
